title: The Safety of PsA-TT in Pregnancy: An Assessment Performed Within the Navrongo Health and Demographic Surveillance Site in Ghana.
abstract: BACKGROUND
  Group A meningococcal disease occurs in large epidemics within the meningitis belt of Africa that includes northern Ghana. Major epidemics in the meningitis belt have infection rates ranging from 100 to 800 per 100 000 population. In 2012, a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), was introduced into the region in large campaigns.
  
  
  METHODS
  We report here on the safety of this vaccine when used in pregnant women in the Navrongo region of Ghana.
  
  
  RESULTS
  Rates of events in 1730 immunized pregnant women and their infants were compared to the rates of the same events in pregnant women who did not receive the vaccine during the campaign and also to women who were pregnant in the prior year.
  
  
  CONCLUSIONS
  We found no evidence of any safety concerns when this vaccine was administered during pregnancy.
authors.affiliation: Navrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana.
authors.forename: George
authors.initials: G
authors.lastname: Wak
authors.affiliation: Navrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana.
authors.forename: John
authors.initials: J
authors.lastname: Williams
authors.affiliation: Navrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana.
authors.forename: Abraham
authors.initials: A
authors.lastname: Oduro
authors.affiliation: Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.
authors.forename: Christine
authors.initials: C
authors.lastname: Maure
authors.affiliation: Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.
authors.forename: Patrick L F
authors.initials: PL
authors.lastname: Zuber
authors.affiliation: Center for Global Health, Cincinnati Children's Hospital, Ohio.
authors.forename: Steven
authors.initials: S
authors.lastname: Black
mesh_terms: D000293:Adolescent; D000328:Adult; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology* / Q000473:pathology*; D005260:Female; D005869:Ghana / Q000453:epidemiology; D006801:Humans; D007231:Infant, Newborn; D008585:Meningitis, Meningococcal / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*; D011358:Product Surveillance, Postmarketing; D055815:Young Adult
chemical_list: C573970:MenAfriVac; D022401:Meningococcal Vaccines
keywords: Ghana; PsA-TT; group A meningococcal vaccine; pregnancy; safety